Search results for "Highlights"
High-sensitivity C-reactive protein level predicted mortality risk in recent-onset type 2 diabetes
While high-sensitivity C-reactive protein was a good predictor of mortality, C-peptide levels were more closely associated with cardiovascular events, and having high levels of both was associated with increased risk of either outcome, a prospective study in Denmark found.
https://diabetes.acponline.org/archives/2023/04/14/1.htm
14 Apr 2023
Severe insulin-resistant diabetes associated with better metabolic surgery outcomes
Patients with severe insulin-resistant diabetes had better outcomes after metabolic surgery than those with mild obesity-related diabetes or severe insulin-deficient diabetes, both in terms of type 2 diabetes remission and renal function, with no additional surgical risk.
https://diabetes.acponline.org/archives/2022/03/11/3.htm
11 Mar 2022
Statins compared for non-HDL cholesterol levels in patients with diabetes
Moderate- and high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin were most effective at moderately reducing levels of non-high-density lipoprotein (HDL) cholesterol, a systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2022/04/08/1.htm
8 Apr 2022
Spotlight on dementia and glycemic control
Prediabetes and diabetes were associated with development of dementia in a South Korean study, and poorly controlled diabetes was tied to increased risk of incident cognitive impairment or progression to dementia in a Swedish study.
https://diabetes.acponline.org/archives/2021/11/12/5.htm
12 Nov 2021
SGLT-2 inhibitors associated with reduced heart failure events versus metformin
A retrospective study of patients who took sodium-glucose cotransporter-2 (SGLT-2) inhibitors or metformin as first-line therapy for type 2 diabetes found similar risk for myocardial infarction and stroke with the two drug classes but a difference in hospitalizations for heart failure.
https://diabetes.acponline.org/archives/2022/06/10/2.htm
10 Jun 2022
GLP-1 receptor agonists linked to increased risk of gallbladder, biliary diseases
A systematic review and meta-analysis of 76 randomized trials found that use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss.
https://diabetes.acponline.org/archives/2022/04/08/2.htm
8 Apr 2022
Manufacturer's trials find positive results for combo drug for type 2 diabetes
Tirzepatide, a not-yet-approved dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, was tested against placebo and semaglutide in recent studies.
https://diabetes.acponline.org/archives/2021/07/09/3.htm
9 Jul 2021
Association of inflammation with mortality in COVID-19 didn't differ by diabetes status
A single-center, case-control study of patients who were hospitalized with COVID-19 found a link between elevated levels of IL-6, IL-8, and interferon-γ-induced protein 10 and mortality risk, regardless of whether patients had type 2 diabetes.
https://diabetes.acponline.org/archives/2022/01/14/2.htm
14 Jan 2022
Obesity increasing in type 1 diabetes, associated with higher risk for chronic kidney disease
Obesity in type 1 diabetes rose from 2004 to 2018, and patients with type 1 had a higher adjusted prevalence of low estimated glomerular filtration rate and albuminuria than those with type 2, an analysis of one health system found.
https://diabetes.acponline.org/archives/2022/02/11/3.htm
11 Feb 2022
HbA1c, CGM data significantly differed in patients with kidney disease
Patients with diabetes and chronic kidney disease often had discordance between their HbA1c levels and continuous glucose monitoring (CGM) data, with the HbA1c being significantly higher on average than the CGM-calculated glucose, a French study found.
https://diabetes.acponline.org/archives/2022/05/13/2.htm
13 May 2022